Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
And inflation in pricing of traditional non Covid challenge studies likely to see price rising from current £4m to £5m per trial.
Barwick, trying to recall something from the Analysts call not reported By wolfi below. Within the £10m deposit, £3m is for preparing the virus For the challenge study.
Barwick, ok PM me and I’ll arrange to send you screenshot of my call history, Slik.
I was on the conference call and confirm the £40m uk gov contract indicated. £10m deposit plus 3 slots x £10m each. In govt facility provided at Royal Free isolation unit in London.
The intensive care beds and the isolation unit are two different things, isolation is level 4. I’d assume discussions ongoing beween parties include hvivo on the number of isolation beds to be configured.
The isolation unit covers half of the top floor of the hospital, so presume space to convert and configure as required by hvivo.
FTSE 250 is a very real possibility in the short term, x5 current market cap.
Especially the Covid challenge model expenditure in Q3 as indicated last night.
CF suggested last night that the delay in profitability from Q3 to Q4 is due to investment in developing the Covid challenge study model. So slightly higher expenditure in the recent past period will bring big multiple rewards when the contracts for Covid challenge studies are announced, starting in next few days with U.K. Govt contract.
CF has previously indicated looking for additional capacity.
PeterS, for me the sensational news is not the single potential contract with UK Government, but the underlying fact that the covid challenge study must be completed and likely to be approved, and so covid vaccine trials can be sold multiple times at £7m every time.
6. Sale of prep bio
7. Sale of immune modulator
5. Sale of Imutex
Interims won’t show profit to June half year accounts but will say company now profit making post period end in second half year. IMO.
JBER dropped off the offer but back on the bid when dropped too far, now repeated several times to confirm the bottom around 12.6. IMO DYOR.
Interesting to see what Berenburg do now not on top of order book for a couple of days. Maybe they'll move back on the bid if it drops to 12.6 as before.
Deep, its looking like your orders may trigger today, I'll be joining you despite being very overweight here already.
Andrew, maybe some of the recent repeat 25k sells too into lower volume?
Interesting that BBurg back on the bid at 13.5p.
The key is watching Berenburg on the order book. Interesting today if they keep the bid at 13.8 or move back on the offer and push it down a tick.
I'd suggest that Acacia are out and Starboard are nearly but not quite out. Volume is lower so sells in smaller less frequent round figure tranches. Berenburg keeping the bid up and raising it gradually, the bottom is possibly around 13.5p now. IMO DYOR.